Dopamine transporter and D2-receptor density in late-onset alcoholism

Abstract Rationale: Late onset type 1 alcoholism has been suggested to be associated with an underlying dopaminergic defect. Therefore, it is relevant to study both postsynaptic D2-receptor and presynaptic dopamine transporter (DAT) densities among alcoholics. Objective: We investigated DAT densities, along with striatal and extrastriatal dopamine D2-receptor densities, in nine non-violent late-onset male alcoholics, who had no major mental disorder nor antisocial personality disorder (ASPD), and nine healthy controls. Methods: [123I]PE2I and [123I]epidepride were used in SPECT imaging. Results: DAT occupancy ratios (striatum/cerebellum) were significantly lower among alcoholics than in controls. Extrastriatal D2-receptor occupancy ratios (temporal pole/cerebellum) were not significantly different between the groups. Conclusions: Striatal presynaptic DAT densities are decreased among type 1 alcoholics, and this finding is not associated with recent alcohol abuse.

[1]  J. Tiihonen,et al.  Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography , 1998, Molecular Psychiatry.

[2]  C. Robert Cloninger,et al.  Neurogenetic adaptive mechanisms in alcoholism. , 1987, Science.

[3]  M Laruelle,et al.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Jari Karhu,et al.  Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics , 1995, Nature Medicine.

[5]  S. Gilman,et al.  Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]Dihydrotetrabenazine and positron emission tomography , 1998, Annals of neurology.

[6]  J S Fowler,et al.  Decreases in dopamine receptors but not in dopamine transporters in alcoholics. , 1996, Alcoholism, clinical and experimental research.

[7]  D Guilloteau,et al.  Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. , 1997, Journal of medicinal chemistry.

[8]  M. First,et al.  Structured clinical interview for DSM-IV axis II personality disorders : SCID-II , 1997 .

[9]  D. Guilloteau,et al.  Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I). , 1998, Nuclear medicine and biology.

[10]  E H Cook,et al.  Brain dopamine transporter messenger RNA and binding sites in cocaine users: a postmortem study. , 1998, Archives of general psychiatry.

[11]  J. Heikkilä,et al.  Dopamine transporters increase in human brain after alcohol withdrawal , 1999, Molecular Psychiatry.

[12]  C. Cloninger.  The psychobiological regulation of social cooperation , 1995, Nature Medicine.

[13]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  J. Karhu,et al.  Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging , 1998, European Journal of Nuclear Medicine.

[15]  M. Tenhunen-Eskelinen,et al.  Physical performance of the Siemens MultiSPECT 3 gamma camera , 1993, Nuclear medicine communications.